Camsing Healthcare's (SGX:BAC) application for an extension of time to hold its annual general meeting for fiscal 2026 and file its annual return was rejected by the Accounting and Regulatory Authority, Singapore, according to a Tuesday bourse filing.
The healthcare company will now look to work with its independent auditors to complete the audit of its financial statements.
Poly Xverse Intelligent Technology (HKG:0209) said its board proposed a share consolidation on the basis of one consolidated share for every 10 issued and unissued shares, according to a Tuesday filing with the Hong Kong bourse.The consolidation will reduce the company's authorized share capital from 70 billion shares to 7 billion consolidated shares.The company's board also proposed changing the board lot size from 10,000 existing shares to 1,000 consolidated shares.The consolidation is subject to shareholder approval and will help the company meet Hong Kong listing requirements.Shares of the toy maker gained nearly 6% in late morning trade Wednesday.
Yutong Bus (SHA:600066) logged May sales volume of 3,480 vehicles, up 14% from 3,053 vehicles the previous year, according to a Tuesday filing with the Shanghai bourse.The bus maker's output rose 4.0% year on year to 3,570 vehicles from 3,434 vehicles.
Nyrada (ASX:NYR) completed a preclinical cardioprotection pilot study that confirmed the feasibility and tolerability of the planned subcutaneous dosing for its Xolatryp lead drug candidate in combination with doxorubicin, according to a Wednesday filing with the Australian bourse.The pilot study aimed to evaluate whether Xolatryp can provide a cardioprotective role in anthracycline chemotherapy, to reduce cardiotoxicity without jeopardizing anti-tumor activity, per the filing.Preliminary biomarker data from the trial showed lower levels of a clinically relevant marker of cardiac injury relative to a control group, the company said.The pilot study was not designed to show statistical significance for an efficacy readout, but it will inform the design of a larger cardiomyopathy study for which results are expected in the third quarter, Nyrada said.The company's shares fell 6% in recent Wednesday trade.